23 May 2012

Analysis Beyond Consensus - Annual Report Analysis - Reliance Industries ::Edelweiss PDF link

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


RIL FY12 AR depicts healthy net cash accretion contributed by BP deal and strong operating cash flows. While profitability on account of BP deal skirts FY12 profits, exchange rate and inventory gains supports operating profits. Investment phase of retail subsidiaries drags consolidated profitability.

FII & DII trading activity across NSE and BSE 23-05-2012

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


CategoryBuySellNet
ValueValueValue
FII1534.161895.23361.07
DII780.79612.3168.49

 

-- 

Market Outlook - 23.04.2012 -Angel Broking - PDF Link

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��



Technical Report - 23.04.2012 -Angel Broking - PDF Link

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��



Derivatives Report - 23.04.2012 -Angel Broking - PDF Link

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��



Market Summary -Angel Broking - 23.05.2012 -PDF link

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��




FII DERIVATIVES STATISTICS FOR 23-May-2012

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


FII DERIVATIVES STATISTICS FOR 23-May-2012 
 BUYSELLOPEN INTEREST AT THE END OF THE DAY 
 No. of contractsAmt in CroresNo. of contractsAmt in CroresNo. of contractsAmt in Crores 
INDEX FUTURES805671902.381141582714.6352090111935.13-812.25
INDEX OPTIONS97029423184.3593447322378.42188693745588.65805.93
STOCK FUTURES829311975.28751971798.0994882821957.81177.19
STOCK OPTIONS36341872.3736639879.12578441401.19-6.74
      Total164.12

-- 

NSE, Bulk deals, 23-May-2012

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


DateSymbolSecurity NameClient NameBuy / SellQuantity TradedTrade Price /
Wght. Avg.
Price
Remarks
23-May-2012GEMINIGemini Communication LimiCSA HOLDINGS PVT LTDBUY5,70,00021.88-
23-May-2012HOTELRUGBYHotel Rugby Ltd.CELEBRITY CONSULTANTS PRIVATE LIMITEDSELL2,00,00017.70-
23-May-2012MICMIC Electronics LimitedSTCI FINANCE LIMITEDSELL11,00,0005.15-
23-May-2012SHALPAINTSShalimar Paints LtdCROSSEAS CAPITAL SERVICES PVT. LTD.BUY21,085593.31-
23-May-2012SHALPAINTSShalimar Paints LtdCROSSEAS CAPITAL SERVICES PVT. LTD.SELL21,085594.91-
23-May-2012VSSLVardhman Spc Steel LtdGUPTA SANJAY DEVKINANDANBUY5,23,33831.00-

BSE, Bulk deals, 23/5/2012

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


Deal DateScrip CodeCompanyClient NameDeal Type *QuantityPrice **
23/5/2012511706Action FinESQUIRE ENCLAVE PRIVATE LIMITEDB7500040.05
23/5/2012511706Action FinGURU KRIPA FINVEST LIMITEDB10000040.05
23/5/2012511706Action FinSANJAY SINGALS17431640.05
23/5/2012531591Bampsl SecAMAN GUPTAB25209111.04
23/5/2012531591Bampsl SecNARAYAN SECURITIES LIMITEDS14954221.04
23/5/2012514312Jaihind SynDINESH JAYNTALAL DOSHIB6421014.19
23/5/2012530165Kanchan IntlSLP TRADERS (SATISH VASANT GHONE )B2399950.20
23/5/2012530165Kanchan IntlVARSHA VINODKUMAR JAINS2399950.20
23/5/2012530039Lords ChemicalsMINI BUILDERS PVT LTDB3550045.09
23/5/2012530039Lords ChemicalsVENKATESWARA CAPITAL MANAGEMENT LIMITEDS5852545.63
23/5/2012530497Marvel CapitalSATISH VASANT GHONES3010022.05

Angel Broking - Tata Steel - RU4QFY2012 - Result Updates -PDF link

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


Tata Steel - RU4QFY2012

May: Pharmaceuticals - Domestic Pharma Monthly Review; : Edelweiss, PDF link

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


The domestic pharma market continued to track strong growth trajectory with 18.4% YoY surge in April 2012 (11% growth last year). Among frontline players, all acute focused companies such as Glenmark, Pfizer and Glaxo India significantly outperformed industry because of strong recovery in segments like anti-infective, gastro and dermatology. Chronic continues to outpace industry growth (21.4% growth) with diabetes growing over 31% during the month. Interestingly, top 50 players’ growth is outpacing industry, highlighting market share consolidation among larger players.
Key takeaways from trends during April
·       Domestic pharma market began on a good note with 18.4% growth in April, significantly higher than 11% YoY growth reported in April 2011.
·       Acute segment has been posting strong growth traction over the past three months with anti-infectives, gastro, derma and multi-vitamins catching up industry growth.
·       Chronic segment continued to remain on a firm trajectory (21.4% growth in April) with allthree segments - diabetes, CVS and CNS  posting strong traction.
·       The MNC pack has been outpacing Indian peers and has outperformed relative to the industry (Pfizer 32%, GSK 24%, Novartis 18% and Abbott 19%).
·       Price increase has been the key growth driver for Pfizer and Glenmark.
·       Cipla is improving consistently and catching up market growth. Other notable highlights are growth recovery in Cadila and Ranbaxy.
·       We see a build-up of inventory for Dr. Reddys (DRRD) at distributor end. We remain concern as DRRD secondary growth is slogging relative to peers, while increase in inventory could boost primary growth but only in short term.
·       Freebies as percentage of sales have been falling consistently; however, in April we have seen little uptake in case of Cipla and Ipca.
·       Growth in respiratory segment for Lupin has dipped to single digit over the past three months (earlier Lupin was gaining market share in respiratory segment).
·       Outperformers:  Glenmark, Pfizer, GSK and Cadila.
·       Underperformers: Dr Reddys, Abbott and Lupin.

DERIVATIVES INFO KIT :May: ShareKhan PDF link

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


DERIVATIVES INFO KIT

Click here to read report: Derivatives Info Kit

Shipping Monitor [ PDF link ] Container spot rates ease further :: CIMB

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


Shipping Monitor  PDF ]
Container spot rates ease further
UNDERWEIGHT - Maintained
- by Raymond YAP, CFA

Last week, the SCFI spot rates fell by up to 4% wow on the US and European trades, suggesting that the weak demand environment is unable to absorb the capacity reactivated for the summer. We forecast another 1½ months of decline until the US peak season in July. Container rates will continue weakening until carriers begin to idle ships from October. We are Neutral on the container shipping sector, with OOIL as our top pick, given the recent sharp share price correction. We remain Underweight on the dry bulk and tanker shipping sectors.

Don't take sick leave on false grounds :: Business Line

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


If one is to go by the number of medical certificates submitted to employers and illnesses confirmed through those certificates, the natural conclusion would be that India has an unhealthy work force which suffers from serious illnesses!
A medical certificate confirming an illness would force the employer to grant leave of absence to an employee whose leave application could have met with rejection otherwise.
In many companies ‘earned leave', ‘privilege leave', can be encashed during service and at the time of retirement. So workers prefer to avail of ‘sick leave' or ‘medical leave', which are not eligible for encashment.
We are, here, concerned with the effect of leave (on medical grounds) on one's life insurance policies. Insurance is a contract of good faith.
In such contracts, two persons enter into the contract with each believing the disclosures made by the other and with the faith that the other person has made a full disclosure.
If at any time it is found that there was no full disclosure or there was suppression of material facts the insurer can repudiate the contract.

SUPPRESSION OF FACTS

This repudiation can be done if it is proved that there was a non-disclosure or suppression of material fact, that the suppression was deliberate, and that the party knew at the time of making the statement that it was false, and if it is found that the suppression has affected the insurer's underwriting decision.
Early claims (by death), from date of commencement or from date of revival, are investigated by life insurance companies.
Let us examine a commonly seen case.
Mr A purchased a life insurance policy on, say, January 1, 2010. In the previous year, Mr A had availed of 30 days leave on medical grounds for supporting his daughter for her preparation for CAT. The year before, Mr A had availed 21 days sick leave submitting medical certificates. This was for undertaking an all-India tour organised by the Railways.

CLAIM INVESTIGATION

In January 2011, Mr A died of some illness. Obviously it was an early death claim.
On the strength of the declaration given in the proposal form authorising employers, doctors and hospitals to give relevant details pertaining to him (the policyholder) to the life insurance company, the insurer, as part of the investigation, requested the employer to supply the leave records of Mr A for the last three or five years.
The leave- records showed that Mr A was absent from duty on health grounds – “not in good health”- for 21 days in 2008 and 30 days in 2009 – and was under the treatment of Government doctors/hospitals.
But he had not disclosed this in the proposal form against the question, “Have you suffered from any illness requiring absence from duty for more than one week?” The obvious decision of the insurer would be to repudiate the claim. The false documents created by Mr A speak against him, to his disadvantage.

THE REMEDY

One can disclose to the insurer that the medical certificate was false and only for the purpose of availing leave. But then the veracity of other answers in the proposal form also comes under the cloud of suspicion.
The best step is not to avail leave of absence on false grounds.
If leave was availed on health grounds, then it must be disclosed in the proposal form. By disclosing an illness suffered, life insurance cover may not be refused. A few clarifications may be asked for, a medical examination may be suggested by the insurer or consideration of the proposal may be postponed for some time.
( The author is President, Society for Promotion of Legal and Insurance Awareness. )

Angel Broking - Siyaram Silk Mills - RU4QFY2012 - Result Updates -PDF link

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


Siyaram Silk Mills - RU4QFY2012

SMART CHART CALLS MOMENTUM CALLS Click here to read report: ShareKhan PDF link

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


PUNTER'S CALL
SidewaysThe Nifty has closed in the positive today and is now expected to head upwards till 4950 with support around 4881 in the immediate run...

SMART CHART CALLS
 


MOMENTUM CALLS
 

Click here to read report: 
EagleEye

Petronet LNG - Buy :Business Line

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��





The recent sharp fall in the stock price of Petronet LNG, the country's largest gas importer and regasifier, provides a good buying opportunity for investors with a long-term perspective. At its current price of Rs 124, the stock trades at around 9 times its trailing 12-month earnings. This is much lower than its historical levels.
After a stellar run last calendar, the Petronet stock has been under pressure from various quarters over the past few months. First, a government proposal in January to have the downstream energy regulator, PNGRB, fix marketing margins of gas companies took a toll.
Then, in early April, the Petroleum and Natural Gas Regulatory Board (PNGRB) directed Delhi-based city gas distributor, Indraprastha Gas, to slash network margins and transmission tariffs by almost 60 per cent.
This led to a sympathetic rout of almost all stocks in the natural gas space, including Petronet LNG. Next, a dip in Petronet's March quarter volumes and profits in comparison to its December 2011 quarter added to the stock's pain.

REGULATORY CONCERNS SUBSIDE

But the concerns seem overdone. PNGRB has recently clarified that regulation of marketing margins of gas companies is outside the purview of powers vested with it currently. This removes a major overhang on the industry and on Petronet LNG. In any case, Petronet has been maintaining that regulation of marketing margins would not apply in its case.
The sequential dip in volumes and profits in the March quarter was mainly a result of maintenance activities by some firms in industries such as fertilisers and power.
Despite reduced off-take, Petronet's capacity utilisation in the March quarter was above 100 per cent, suggesting robust demand. Besides, the December 2011 quarter was better-than-usual for the company; hence the sequential dip in March quarter does not mean trouble regarding the company's business prospects. Overall, in FY-12, Petronet's capacity utilisation was a healthy 107 per cent.

VOLUME GROWTH

Demand for imported gas, though costlier than domestic gas, is growing at a healthy pace in India. This is due to the cost advantages of natural gas over competing fuels, and the continuing dip in domestic gas production, primarily from the KG-D6 fields of Reliance Industries.
Petronet has been able to make the most of the opportunity, growing its FY-12 sales and profits by more than 70 per cent. Demand continues to grow, but Petronet currently operates at more than full capacity.
Hence, volumes, while remaining healthy, may not show significant growth in the near term, till new capacities, which are work-in-progress become operational. Petronet is expanding capacity at its Dahej terminal from 10 million tonnes per annum (mtpa) to 15 mtpa. It is also setting up a 5 mtpa plant at Kochi.
The Kochi plant is expected to be commissioned by end-2012. The second terminal at Dahej, which should increase capacity to 12.5 mtpa, is expected to be completed by October 2013, while the full expansion to 15 mtpa should be over by end-2015.
Also, Petronet has signed a term-sheet for setting up a 5 mtpa terminal at Gangavaram port in Andhra Pradesh. Besides, the expanding gas pipeline network in the country, which includes currently under-served regions such as South India, should provide new markets for Petronet and aid its capacity utilisation. All this should translate into robust volume growth for the company in the coming years.

WELL-POSITIONED

Even if domestic gas output in the country picks up, the wide gap between expected demand (434 mmscmd) and domestic supply (203 mmscmd) by 2015 provides enough room for LNG players. Petronet, thanks to its size advantage, should benefit.
The company's comfortable leverage level (debt-to-equity of 0.93) provides adequate leeway to fund expansion plans.